Development of small-molecule PCSK9 inhibitors for the treatment of hypercholesterolemia.
Sign Up to like & getrecommendations! Published in 2022 at "Drug discovery today"
DOI: 10.1016/j.drudis.2022.01.014
Abstract: When secreted into the circulation, proprotein convertase subtilisin kexin type 9 (PCSK9) blocks the low-density lipoprotein receptors (LDL-R) and, as a consequence, low-density lipoprotein cholesterol (LDL-C) levels increase. Therefore, PCSK9 has emerged as a potential… read more here.
Keywords: small molecule; pcsk9 inhibitors; molecule pcsk9; pcsk9 ... See more keywords